The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute lymphoblastic leukemia (ALL), the development of experimental models to probe mechanisms and evaluate new therapies, and the development of more efficacious treatment stratification. Genomic analyses have revolutionized our understanding of the molecular taxonomy of ALL, and these advances have led the push to implement genome and transcriptome characterization in the clinical management of ALL to facilitate more accurate risk-stratification and, in some cases, targeted therapy. Although mutation- or pathway-directed targeted therapy (e.g., using tyrosine kinase inhibitors to treat Philadelphia chromosome [Ph]-positive and Ph-like B-cell-ALL) is currently available for only a minority of children with ALL, many of the newly identified molecular alterations have led to the exploration of approaches targeting deregulated cell pathways. The efficacy of cellular or humoral immunotherapy has been demonstrated with the success of chimeric antigen receptor T-cell therapy and the bispecific engager blinatumomab in treating advanced disease. This review describes key advances in our understanding of the biology of ALL and optimal approaches to risk-stratification and therapy, and it suggests key areas for basic and clinical research.

Introduction

Contemporary childhood ALL studies have shown improved 5-year overall survival (OS) rates exceeding 90% (Table 1). However, OS for the St. Jude Total Therapy Study XVI (94.3%) was similar to that for the Total Therapy Study XV (93.5%) (Figure 1). Therefore, with the conventional approach, the chemotherapy intensity has been raised to the limit of tolerance, and further improvements in outcomes and reduction of adverse effects will require novel therapeutic approaches. Historically, genetic factors identified by conventional karyotyping have been used to diagnose ALL and to risk-stratify children with the disease. However, the alterations thus identified, including hyper- and hypodiploidy and several chromosomal rearrangements, did not establish the basis of ALL in a substantial minority of children; nor did they satisfactorily reveal the nature of the genetic alterations driving leukemogenesis. Genomic studies have now clarified the subclassification of ALL and have demonstrated a close interplay between inherited and somatic genetic alterations in the biology of ALL. Many of these alterations have important implications for diagnosis and risk-stratification of ALL and for the use and development of novel and targeted approaches.

Heritable susceptibility to acute lymphoblastic leukemia

Several lines of evidence indicate that there is a genetic predisposition to acute lymphoblastic leukemia (ALL), at least in a subset of cases. This evidence includes the existence of: (i) rare constitutional syndromes with increased risk for ALL; (ii) familial cancer syndromes; (iii) non-coding DNA polymorphisms that subtly influence the risk of ALL; and (iv) genes harboring germline non-silent variants presumed to confer a risk of sporadic ALL. Constitutional syndromes such as Down syndrome and ataxia-telangiectasia are associated with increased risk of B-cell-ALL (with CRLF2 rearrangement) and T-cell-ALL, respectively. Familial cancer syndromes such as Li-Fraumeni syndrome, constitutional mismatch repair deficiency syndrome, or DNA repair syndromes (e.g., Nijmegen breakage) have an increased
incidence of malignancy in general. Familial predisposition specific to leukemia is uncommon but has resulted in the identification of predisposing non-silent variants that are also observed in sporadic ALL cases, including TP53 germline mutations and low hypodiploid B-ALL, ETV6 variants and hyperdiploid ALL, and PAX5 mutations and B-ALL with dicentric/isochromosome 9. These susceptibility genes are targets of somatic mutation in ALL: ETV6 and PAX5 are rearranged, amplified/deleted, and mutated in B-ALL,14,15 as is TP53 in hypodiploid ALL.10 Germline variants of IKZF1 are observed in familial B-ALL and immunodeficiency,16,17 and somatic IKZF1 alterations are enriched in Philadelphia chromosome (Ph)-positive, Ph-like, and DUX4-rearranged B-ALL.18-20 RUNX1 germline

### Table 1A. Treatment results for acute lymphoblastic leukemia in major pediatric clinical trials.

| Study                  | Years of study | Subtype | Age (y) | Patients (n) | Steroid during induction (mg/m²/day) | MTX (g/m²/dose) | Cranial irradiation | Complete remission (%) | Cumulative incidence of relapse (5y, 95% CI) | Death in remission (5y, 95% CI) | Event-free survival (5y, %) | Overall survival (5y, %) |
|------------------------|----------------|---------|---------|--------------|--------------------------------------|-----------------|---------------------|------------------------|-----------------------------------------------|---------------------------------|-----------------------------|--------------------------|
| AIEOP/BFM              | 2000-2006      | B and T | 1-17    | 3720         | Pred 60 (1887 pts) / Dex 10 (1853 pts) / [R] | Pred: 97.8/Dex: 97.8 (P=0.001) | Pred: 1.7/Dex: 2.3 (P=0.024) | Pred: 80.8/Dex: 83.9 (P=0.054) | Pred: 90.5/Dex: 90.3 (P=0.005) | Pred: 85.0/Dex: 88.9 (P=0.005) | Pred: 95.5/Dex: 90.5 (P=0.05) |
| COG ALL0331           | 2005-2010      | B, SR   | 1-9     | 5377         | Pred 60 (427 pts)/ Dex 10 (424 pts) / [R] (aged 1-9y) | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] |
| COG ALL0434           | 2007-2014      | T       | 1-30    | 1562         | Pred 60 (512 pts)/ Dex 10 (519 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] |
| DFCl ALL Consortium   | 2005-2010      | B and T | 1-18    | 551          | Pred 40 (232 pts) / Pred 60 (232 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] |
| MRC UK ALL 2003       | 2003-2011      | B and T | 1-24    | 3126         | Pred 60 (232 pts) / Pred 60 (232 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] |
| NOPOH ALL2008         | 2008-2014      | B and T | 1-45    | 1569         | Pred 60 or Dex 10 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] |
| SJCRH Total XVI       | 2007-2017      | B and T | 0-18    | 538          | Pred 40 (232 pts) / Pred 60 (232 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] | Pred 60 (1853 pts) / Dex 10 (1853 pts) / [R] |

---

haematologica | 2020; 105(11)
mutations can lead to both T-ALL and AML, and \(ETV6\) variants predispose carriers to B-ALL and myelodysplasia.\(^{21,22}\)

Genome-wide association studies (GWAS) have identified non-coding variants in at least 13 loci associated with ALL. The relative risk associated with each variant is typically low (corresponding to an increase of up to 1.5- or 2-fold) but cumulatively, they may result in an increase of up to 10-fold in ALL risk. Risk variants are frequently at/near hematopoietic transcription factor or tumor suppressor genes, including \(ARID5B, BAK1, CDKN2A/CDKN2B, BMI1-PIP4K2A, CEBPE, ELK3, ERC, GATA3, IGF2BP1, IKZF4, IKZF3, USP7,\) and \(LHPP.\)\(^{23-25}\) Several variants display ancestry and ALL subtype-specific associations, such as those of \(GATA3\) with Hispanics and \(PH\)-like B-ALL, \(ERG\) with African Americans and \(TCF3-PBX1\) B-ALL, and \(USP7\) with African Americans and T-ALL with \(TAL1\) deregulation.\(^{26-28}\)

Finally, germline genomic analysis has identified additional susceptibility variants in sporadic hyperdiploid B-ALL (\(NBN, ETV6, FLT3, SH2B3,\) and \(CREBBP\), Down syndrome-associated B-ALL (\(IKZF4, NBN, RTEL1\)), and T-ALL (Fanconi-BRCA pathway mutations).\(^{29-31}\)

**Prenatal origin of leukemia**

Several lines of investigation indicate that a subset of childhood leukemia cases arise before birth.\(^{32,33}\) Chromosomal translocations, particularly \(ETV6-RUNX1\) (\(TEL-AML1\)) may be detected at birth in blood spots and cord blood years before the clinical onset of leukemia, providing support for a multi-step process of leukemogenesis. This is supported by genomic analyses of monozygotic, monochorionic twins concordant for leukemia, showing genetic identity of initiating lesions and discordance for secondary genetic alterations indicating inter-twin, intrauterine transmission of leukemia.\(^{34,35}\) Evidence for \(in\)-\(utero\) origin is strongest for \(KMT2A\)-rearranged and \(ETV6\)-\(RUNX1\) ALL. Ancedotal evidence supports \(in\)-\(utero\) origin for other subtypes of B-ALL, including hyperdiploid and \(ZNF384\)-rearranged leukemia.\(^{36}\)

**Genetics of B-cell acute lymphoblastic leukemia**

-B-cell acute lymphoblastic leukemia (B-ALL) is the most common form of ALL, comprising >20 subtypes of variable prevalence according to age that are associated with distinct gene expression profiles and are driven by three main types of initiating genetic alteration: chromosomal aneuploidy, rearrangements that deregulate oncogenes or encode chimeric transcription factors, and point mutations (Table 2 and Figure 2). Each subtype typically has co-occurring genetic alterations that perturb lymphoid development, cell-cycle regulation, and kinase signaling and chromatin regulation, and the genes involved and their frequency of involvement vary between subtypes.\(^{30}\)

High hyperdiploidy (>50 chromosomes) is present in up to 50% of childhood ALL and is associated with mutations in the Ras pathway, chromatin modifiers such as \(CREBBP\), and favorable outcomes.\(^{37}\) Low hypodiploidy (51-59 chromosomes) is present in approximately 1% of children with ALL but in >10% of adults. It is characterized by the deletion of \(IKZF2\) and by near-universal \(TP53\) mutations, which are inherited in approximately half the cases.\(^{38}\) Near haploidy (24-30 chromosomes) is present in approximately 2% of pediatric ALL and is associated with Ras mutations (particularly \(NF1\)) and deletions of \(IKZF3\). Both low-hypodiploid and near-haploid ALL are associated with unfavorable outcomes. The prevalence of hypodiploidy may be underestimated because of the phenomenon of “masked” hypodiploidy, in which the hypodiploid genome is duplicated, leading to a hyperdiploid modal chromosome number.\(^{10,30}\) Distinguishing masked-hypodiploid ALL from high-hypodiploid ALL is important in view of the genetic (germline \(TP53\) alterations) and prognostic implications. Masked hypodiploidy may be suspected by the patterns of chromosomal gain (commonly diploid and tetrasomic chromosomes, rather than trisomies in high-hypodiploid ALL) and may be formally confirmed by flow cytometric analysis of the DNA index, which commonly shows peaks for both non-masked and masked clones, and by techniques that assess loss of heterozygosity, such as SNP...
arrays. In addition, the transcriptomic profiles and co-occurring genetic alterations (e.g., Ras pathway and CREBBP alterations) of near-haploid and high-hyperdiploid ALL are similar, suggesting a common origin for these entities. ALL with intrachromosomal amplification of chromosome 21 (iAMP21) is most common in older children and is associated with poor prognosis, which has been improved with intensive treatment. Of the subtypes characterized by translocations, the most common in childhood B-ALL is t(12;21)(p13;q22) encoding ETV6-RUNX1, which is typically cryptic on cytogenetic analysis and is associated with favorable prognosis. The t(1;19)(q23;p13) translocation and variants encode TCF3-PBX1, which is more common in African Americans and is associated with more frequent central nervous system (CNS) relapse and inferior outcomes with older, but not contemporary, treatment regimens. The t(9;22)(q34;q11.2) translocation results in the formation of the Philadelphia chromosome that encodes BCR-ABL1 and is found in a subset of childhood ALL that was also associated with unfavorable outcomes, although the prognosis has now been improved with combined chemotherapy and tyrosine kinase inhibition. Rearrangement of KMT2A (MLL) at 11q23 to >80 partners, most commonly t(4;11)(q21;q23) encoding KMT2A-AFF1, is common in infant ALL and is associated with a dismal prognosis.

Genomic analyses, particularly transcriptome sequencing, have identified multiple new subtypes not evident on cytogenetic analysis because of cryptic and/or diverse rearrangements or sequence mutations acting as driver lesions. ETV6-RUNX1–like ALL is characterized by a gene expression profile and immunophenotype (CD27+, CD44 low/negative) similar to that of ETV6-RUNX1 ALL. Such patients harbor alternate gene fusions or copy number alterations in ETS-family transcription factors (ETV6, ERG, FLI1), IKZF1, or TCF3. ETV6-RUNX1–like ALL occurs almost exclusively in children (representing ~3% of pediatric ALL) and is associated with relatively favorable prognosis. Translocation of DUX4, encoding a double-homeobox transcription factor, to the immunoglobulin heavy-chain locus (IGH) is also cytogenetically cryptic and is found in 5-10% of B-ALL. The translocation results in overexpression of DUX4 protein lacking the C-terminal domain. This truncated protein binds an intragenic region of the ETS-family transcription factor ERG (ETS-related gene), resulting in profound transcriptional deregulation of ERG. This in turn commonly results in expression of a C-terminal ERG protein fragment and/or ERG deletion. DUX4-rearranged B-ALL has a distinctive gene expression profile and immunophenotype (CD2+, CD37−), and despite the deletion of IKZF1 (otherwise an adverse prognostic factor in ALL) in approximately 40% of cases, the outcome is typically excellent.

ZNF384 rearrangement defines a distinct group of acute leukemias that may manifest as B-ALL (often with aberrant myeloid marker expression) or B/myeloid mixed-phenotype acute leukemia (MPAL; MPO-positive leukemia). ZNF384 rearrangement is observed in 6% of childhood B-ALL and in 48% of childhood (but notably not adult) B/myeloid MPAL. ZNF384-like cases, often with ZNF362 rearrangements, are also observed. Both ZNF384 and ZNF362 encode C2H2-type zinc-finger tran-
scription factors and are rearranged with genes encoding N-terminal transcription factors (e.g., TAF15 and TCF3) or chromatin modifiers (most commonly EP300, but also CREBBP, SMARCA2, and ARID1B). ZNF384-rearranged leukemia is associated with elevated FLT3 expression, and there are anecdotal reports of profound responses to FLT3 inhibition. ZNF384-rearranged leukemia may shift during the disease course and may result in loss of CD19 expression and failure of chimeric antigen receptor T-cell therapy.

MEF2D (myocyte enhancer factor 2D)-rearranged ALL (occurring in 4% of children and up to 10% of adults with ALL) has a distinct immunophenotype (CD10−, CD38+), an older age of diagnosis (median: 14-15 years), and a poor prognosis. The rearrangements result in increased HDAC9 expression and sensitivity to histone deacetylase inhibitor treatment.

NUTM1 (nuclear protein in testis midline carcinoma family 1) rearrangements are observed in 1-2% of childhood B-ALL, with fusion to genes encoding various transcription factors and epigenetic regulators (e.g., ACIN1, BRD9, CUX1, IKZF1, SLC12A6, and ZNF618) that drive aberrant NUTM1 expression. In all fusions, the NUT domain is retained, and this is hypothesized to lead to global changes in chromatin acetylation and to sensitivity to histone deacetylase inhibitors or bromodomain inhibitors. ALL with NUTM1 rearrangements has an excellent prognosis.

Other transcription factor-driven subtypes of B-cell acute lymphoblastic leukemia

Two B-ALL subtypes have distinct alterations of the lymphoid transcription factor PAX5. PAX5-altered (PAX5alt) B-ALL accounts for 10% of childhood B-ALL, with cases featuring diverse PAX5 alterations, including rearrangements (most commonly with ETV6 or NOL4L), sequence mutations or intragenic amplification, and an intermediate prognosis. PAX5 P80R B-ALL accounts for approximately 2% of childhood B-ALL, with cases featuring universal P80R mutation and deletion/mutation of the remaining allele, mutations in Ras and JAK2 signaling genes, and an intermediate to favorable prognosis. A single heterozygous mutation in IKZF1 (N159Y) defines a novel subtype of ALL (representing <1% of cases) with IKZF1 nuclear mislocalization, enhanced intercellular adhesion, and expression of genes involved in oncogenesis (YAP1), chromatin remodeling (SALL1), and JAK-STAT signaling.

Kinase-driven subtypes

Of therapeutic relevance are the two kinase-driven subtypes: Philadelphia chromosome-positive (Ph+ or BCR-ABL1+) and Philadelphia chromosome-like (Ph-like or BCR-ABL1-like) ALL. Their frequency increases with age.

Figure 2. Distribution of B-cell acute lymphoblastic leukemia (B-ALL) subtypes within each age group. SR: standard risk; HR: high risk; WBC: white blood cell count; AYA: adolescent and young adult.
Table 2. Genetic alterations, age distribution, clinical features, and genetic-based therapy in pediatric B- and T-acute lymphoblastic leukemia.

| Category                                      | Age      | Description                                                                                                                                     | Potential therapeutic implications                        |
|-----------------------------------------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| **B-cell precursor acute lymphoblastic leukemia** |          |                                                                                                                                                 |                                                             |
| Hyperdiploidy with more than 50 chromosomes   | Children >> adults | Excellent prognosis; mutations in Ras signaling pathway and histone modifiers                                                                  | Reduction of intensity                                      |
| Near-haploid                                   | Children-adults | 24-31 chromosomes; poor prognosis; Ras-activating mutations; inactivation of IKZF3                                                            | BCL2 inhibitors                                             |
| Low hypodiploid                                | Children < adults | 32-39 chromosomes; poor prognosis; TP53 mutations (somatic and germline)                                                                       | BCL2 inhibitors                                             |
| iAMP21                                         | Older children | Complex alterations of chromosome 21; requires high-risk therapy for good outcomes                                                                | Intensification of therapy                                  |
| t(12;21)(p13;q22) encoding ETV6-Runx1          | Children >> adults | Excellent prognosis; cryptic rearrangement that is detectable by FISH                                                                          | Reduction of intensity                                      |
| ETV6-Runx1-like                               | Children > adults | Absence of ETV6-Runx1 fusion; mutations in both ETV6 and IKZF1                                                                                 | Reduction of intensity                                      |
| t(1;19)(q23;p13) encoding TCF3-PBX1            | Children-adults | Increased incidence in African Americans; favorable prognosis                                                                                |                                                             |
| t(9;22)(q34;q11.2) encoding BCR-ABL1           | Children < < adults | Historically poor prognosis; improved with tyrosine kinase inhibitors; common deletions of IKZF1                                               | ABL1 inhibitors, FAK inhibitors, rexinoids, BCL2 inhibitors  |
| Ph-like                                        | Children < adults | Kinase-activating lesions; poor outcome; potentially amenable to kinase inhibition                                                              | ABL1 inhibitors, JAK inhibitors, PI3K inhibitors, BCL2 inhibitors |
| CRLF2 rearranged (IGH-CRLF2; P2RY3-CRLF2)      | Children < adults | Common in Down syndrome and Ph-like ALL; associated with IKZF1 deletion and JAK2 mutation                                                    | JAK inhibitors, BCL2 inhibitors                             |
| KMT2A (MLL) rearranged                        | Infants << children-adults | Common in infant ALL; dismal prognosis; few co-operating mutations, commonly in RAS signaling pathway                                   | DOT1L inhibitors, menin inhibitors, proteasome inhibitors, HDAC inhibitors, BCL2 inhibitors |
| DUX4 rearranged and ERG deregulated           | Children-adults | Distinct gene expression profile; most have focal ERG deletions and favorable outcome despite IKZF1 alterations                              | Reduction of intensity                                      |
| MEF2D rearranged                              | Children-adults | Distinct gene expression profile; potential sensitivity to HDAC inhibition                                                                      | HDAC inhibitors                                             |
| ZNF384 rearranged                             | Children < adults | Pro-B ALL phenotype; expression of myeloid markers; increased expression of FLT3                                                               | FLT3 inhibitors                                             |
| **PAX5alt**                                   | Children > adults | PAX5 fusions, mutation, or amplifications; intermediate prognosis                                                                             |                                                             |
| **PAX5 P80R**                                 | Children < adults | Frequent signaling pathway alterations                                                                                                          | Kinase inhibitors                                           |
| **IKZF1 N159Y**                               | Children-adults | Rare; unknown prognosis                                                                                                                       | FAK inhibitors, rexinoids                                   |
| **NUTM1**                                     | Children-adults | Exclusively in children; rare; excellent prognosis                                                                                             | HDAC inhibitors, bromodomain inhibitors                     |
| t(17;19)(q22;p13) encoding TCF3-HLF            | Children-adults | Rare; dismal prognosis                                                                                                                        | BCL2 inhibitors                                             |
| BCL2/MYC rearranged                           | Children < adults | Poor prognosis                                                                                                                               |                                                             |
| **T-lineage acute lymphoblastic leukemia**     |          |                                                                                                                                                 |                                                             |
| TAL1 deregulation                             | Children-adults | Enrichment of mutation in PI3K signaling pathway                                                                                               | PI3K inhibitors, nelarabine, BCL2 inhibitors               |
| TLX3 deregulation                             | Children-adults | Poor prognosis; frequent co-operating mutation in ubiquitination and ribosomal genes                                                          | Nelarabine, BCL2 inhibitors                                 |
| HOX4 deregulation                             | Children-adults | Frequent mutations in JAK-STAT pathway, KMT2A rearrangements                                                                                  | JAK inhibitors, nelarabine, BCL2 inhibitors                |
| TLX1 deregulation                             | Children > adults | Favorable prognosis                                                                                                                           | Nelarabine, BCL2 inhibitors                                 |
| LMO2/LYL1 deregulation                       | Children-adults | Poor prognosis; enriched for ETP-ALL, frequent co-operating mutation in JAK-STAT                                                             | JAK inhibitors, nelarabine, BCL2 inhibitors                |
| **NKL2-I deregulation**                       | Children-adults | Frequent co-operating mutation in ribosomal genes                                                                                              | Nelarabine, BCL2 inhibitors                                 |
| **NUP214-ABL1 with 9q34 amplification**       | Children-adults | Neutral prognosis, in contrast to kinase driven B-ALL; potentially amenable to tyrosine kinase mutation                                         | ABL1 inhibitors, nelarabine, BCL2 inhibitors               |
| Early T-cell precursor ALL                    | Children-adults | Poor prognosis; genetically heterogeneous with mutations in hematopoietic regulators, cytokine and Ras signaling, and epigenetic modifiers | JAK inhibitors, BCL2 inhibitors                             |

FISH: fluorescence in situ hybridization; ALL: acute lymphoblastic leukemia; HDAC: histone deacetylase.
and they account for 25% and 20%, respectively, of adult ALL. The prevalence of BCR-ABL1 ALL rises progressively from <20% of ALL in adults younger than 25 years to more than half of adults aged 50-60 years, whereas the prevalence of Ph-like ALL peaks in young adulthood, and this subtype is observed in up to 25% of adults. Alterations of B-lineage transcription factor genes, particularly IKZF1, are a hallmark of BCR-ABL1 ALL and are a key determinant of lymphoid lineage and resistance to therapy. IKZF1 alterations are associated with poor outcome in ALL overall, particularly because of the high prevalence in BCR-ABL1 and Ph-like ALL; however, they are not associated with poor outcome in DUX4-rearranged ALL. This has led to the definition of “IKZF1-plus” as a marker of poor outcome in ALL, being defined by the presence of alterations in IKZF1 and CDKN2A/B, PAX5, or pseudoautosomal region 1 (PAR1, as a surrogate for CRLF2 rearrangement), but not ERG (as a surrogate for DUX4-rearranged ALL), commonly detected by multiplex ligation-dependent probe amplification (MLPA). Although used for risk-stratification in several clinical trials, the utility of this approach is limited by the inability of MLPA to identify all cases with key high-risk (CRLF2 rearrangement) and favorable-risk (DUX4 rearrangements) that co-occur with IKZF1 alterations.

Ph-like ALL has a similar transcriptional profile to Ph-positive ALL but is BCR-ABL1 negative. It is genetically heterogeneous with multiple rearrangements (e.g., of CRLF2, ABL-class genes, JAK-STAT signaling genes, FGFR1, and/or NTRK3), copy number alterations, and sequence mutations that activate tyrosine kinase or cytokine receptor signaling (Figure 3). Ph-like ALL is associated with elevated minimal residual disease (MRD) levels and/or high rates of treatment failure. The diverse genetic alterations characteristic of Ph-like ALL and its responsiveness to tyrosine kinase inhibitors (at least for ABL-class and NTRK3-rearranged ALL) have spurred the use of RNA-sequencing approaches to identify such alterations at diagnosis and direct patients to targeted therapy.

Genetic basis of T-cell acute lymphoblastic leukemia

Childhood T-cell acute lymphoblastic leukemia is characterized by recurrent alterations in ten pathways, but in most cases, three pathways are deregulated: expression of T-lineage transcription factors, NOTCH1/MYC signaling, and cell-cycle control. Gene expression profiling enables classification of >90% of T-ALL into core subgroups defined by deregulation of T-ALL transcription factors as a result of rearrangement with T-cell receptor enhancers, structural variants, or enhancer mutations of TAL1, TAL2, TLX1, TLX, HOXA, LMO1/LMO2, LMO2/LYL1, or NXX2-1 (Table 2). A more recently described mechanism of deregulation is through small insertion/deletion mutations upstream of TAL1, which lead to a new binding motif for MYB or TCF1/TCF2 and subsequent changes in TAL1 expression. A similar mechanism has been described for other oncogenes in T-ALL, including LMO2. Additional transcription factor genes, including ETV6, RUNX1, and GATA3, are altered by deletion or sequence mutation but are not subtype-defining. The second core transcriptional pathway mutation found in most T-ALL cases is aberrant activation of NOTCH1, a critical transcription factor for T-cell development. Constitutive NOTCH1 activity, caused by activating NOTCH1 mutations (in >75% of cases) and/or inhibitor mutations in the negative regulator FBXW7 (in 25% of cases), promotes uncontrolled cell growth, partly through increased MYC expression. The third core alteration observed in pediatric T-ALL is deletion of tumor suppressor loci, primarily CDKN2A/CDKN2B (in 80% of cases) and, less commonly, CDKN1B, RB1, or CCND3.

In addition to the aforementioned core alterations, T-ALL frequently involves derangement of additional transcriptional regulators (MYB, LEF1, and BCL11B), ribosomal function, ubiquitination through loss-of-function USP7 mutations, RNA processing, signaling pathways, and epigenetic modifiers such as PHF6, KDM6A, and genes of polycomb repressive complex 2 (EED, SUZ12, and EZH2). The signaling pathway most commonly activated is PI3K-AKT, through loss of negative regulation by PTEN. JAK-STAT pathway activation can occur through gain-of-function mutations in IL7R, JAK1, JAK3, or STAT5B or through loss-of-function alterations in the JAK-STAT regulators PTPN2 and SH2B3, whereas mutations in RAS-MAF signaling are less common, except in early T-cell precursor (ETP) ALL. Kinase rearrangements are observed in a minority of cases, particularly the NUP214-BCL1 rearrangement.

Genetics of relapse

The subclonal complexity of ALL is now well established, and the clonal dynamics during therapy and at relapse have been examined through genomic sequencing and single-cell analysis. Chimeric fusions, when present, are often clonal leukemia-initiating lesions that are typically retained throughout disease progression. Alterations of signaling pathway lesions (FLT3, KRRS, NRAS) are often subclonal and are frequently lost or gained between diagnosis and relapse.

In B-ALL, mutations in genes such as the histone acetyl transferase gene CREBBP, the histone methyltransferase gene SETD2, and the steroid receptor genes NRSN1 and NRSN2 are enriched at relapse. At diagnosis, minor relapse-initiating subclones can exhibit inherent resistance to chemotherapy, even before secondary mutation acquisition. Other relapse-specific mutations in PRPS1, PRPS2, NT5C2, or MSH6, each influencing thiopurine metabolism, may emerge only during therapy, being driven by selective therapeutic pressure. These mutations confer chemotherapy resistance and might have implications for disease monitoring and therapeutic decisions. Inherited genomic variants in specific ethnic/racial groups also contribute to relapse risk as a result of differential drug metabolism or acquisition of distinct somatic mutations. Monitoring the dynamics of mutation clearance during induction therapy or monitoring for the emergence of relapse-associated mutations might identify patients who will benefit from early modification of therapy.

Mixed-phenotype acute leukemia

Mixed-phenotype acute leukemia (MPAL) is uncommon, representing only 2-5% of pediatric acute leukemia. The 2016 World Health Organization (WHO) classification defines MPAL as acute leukemia expressing a combination of antigens not restricted to a single lineage with the following categories: B/myeloid, not otherwise specified (NOS) and T/myeloid, NOS, in addition to two genetic subgroups of MPAL: that with t(9;22) (q34.1;q11.2), BCR-ABL1; and that with t(11;14)(q23.5); KMT2A-rearranged. Genetic characteriza-
Rearrangement of pediatric MPAL revealed that rearrangement of ZNF384 is common in B/myeloid MPAL and biallelic WT1 alterations are common in T/myeloid MPAL, which shares genomic features with ETP ALL. Such genetic alterations are consistent with the results of a retrospective multinational study showing that ALL-type therapy is more effective than AML- or combined-type treatment in patients with MPAL. Furthermore, the immunophenotypic heterogeneity within MPAL populations is not driven by distinct genomic subclones. Such a phenotypic fate results from the acquisition of mutations in early hematopoietic progenitors with preserved myeloid and lymphoid potentials, and individual phenotypic subpopulations can reconstitute the immunophenotypic diversity.

Risk assignment for treatment

Age (infant or ≥10 years), white blood cell (WBC) count at diagnosis (≥50×10⁹/L), central nervous system (CNS) involvement, T-cell immunophenotype, race (Hispanic or black), and male sex have been considered clinical adverse prognostic factors (Table 3). Furthermore, certain somatic genetic alterations are significantly associated with outcome and can partly explain the clinical factors. For example, patients with hyperdiploidy (>50 chromosomes or DNA index >1.16) and ETv6-RUNX1 have a better prognosis and are commonly young children with low WBC counts. Conversely, patients with hypodiploidy (<44 chromosomes), Ph-positive or Ph-like ALL, KMT2A, MEF2D, or BCL2/MYC rearrangements, or TCF3-HLF have worse prognoses and are more commonly adolescents or adults with higher WBC counts and/or CNS involvement. Hispanic patients have greater incidences of Ph-like ALL with CRLF2 fusions. Infant leukemia is strongly associated with KMT2A rearrangements.

Early response to chemotherapy in terms of MRD is another important prognostic factor. MRD can be measured by flow cytometry for leukemia-specific aberrant immunophenotypes or by polymerase chain reaction (PCR) for unique immunoglobulin and T-cell receptor genes or fusion transcripts. Next-generation sequencing is more sensitive than flow cytometry or PCR for MRD detection, but the superiority of this methodology for clinical application needs to be confirmed in larger studies. The relapse risk at a given MRD level differs between genetic subtypes. Patients with favorable genetic subtypes have lower MRD levels than those with high-risk genetics and T-ALL. Although patients with high-risk genetic features remain at risk for relapse even with undetectable or very low level (e.g., <0.01%) MRD at the end of induction, low-level MRD can be overcome in patients with low-risk features by subsequent treatment. Current treatment protocols incorporate clinical factors, leukemia genetics, and MRD for risk-stratification.

Treatment

Treatment of ALL comprises three phases: remission induction, consolidation (or intensification), and maintenance.
nance (or continuation), and lasts for 2-2.5 years. Most conventional chemotherapy regimens were developed before 1970, and the optimal dosages and schedules for combination chemotherapy were developed with dose adjustments based on tolerability, response evaluation with MRD, and individualized pharmacodynamic and pharmacogenomic studies, but with limited use of the biological features of ALL cells obtained through genomic analyses. Allogeneic hematopoietic cell transplantation (HCT) has been used for patients at very high risk. In the last decade, molecularly targeted agents and immunotherapy have emerged as novel therapeutic strategies.

Survivors treated before 1990 experienced late effects in multiple organ systems (e.g., reproductive, neurological, or gastrointestinal effects or infections), but those treated on more recent protocols have experienced predominantly musculoskeletal effects, possibly due to more intensive use of dexamethasone and asparaginase.\textsuperscript{94} In addition, cranial radiotherapy-induced hypothalamic dysfunction has given way to impaired glucose metabolism and obesity as the use of radiotherapy has been reduced. The recent pattern of late effects could be managed by prevention or intervention as well as by rational reduction of conventional chemotherapy combined with molecularly targeted therapy and immunotherapy.

**Remission-induction therapy**

Remission-induction therapy consists of three drugs (glucocorticoid [prednisone or dexamethasone], vincristine, and asparaginase) or four drugs (the 3 aforementioned drugs plus anthracycline) administered over 4-6 weeks and induces complete remission (CR) in approximately 98% of pediatric patients.

Compared to prednisone, dexamethasone has a longer half-life and better CNS penetration, which improves CNS disease control.\textsuperscript{92} In randomized studies comparing prednisone and dexamethasone, patients who received dexamethasone had better event-free survival (EFS) than did those who received prednisone at a prednisone-to-dexamethasone dose ratio of <7 (Table 1).\textsuperscript{1,97} However, OS was similar in both arms, except in one study that found dexamethasone beneficial in patients with T-ALL who had a good prednisone-prophase response.\textsuperscript{1} Furthermore, dexamethasone is associated with more frequent adverse effects, such as infection, bone fracture, osteonecrosis, mood/behavior problems, and myopathy. When the dose ratio was >7, there was no difference in outcomes with the two glucocorticoids.\textsuperscript{97} Therefore, the dose, schedule, and type of glucocorticoid are determined based on the patient’s age, relapse risk, and treatment phase. Bacterial infection can be reduced with prophylactic antibiotics, such as levofloxacin during neutropenia.\textsuperscript{98,99} Alternate-week dexamethasone administration, as opposed to a continuous schedule, can reduce the risk of osteonecrosis.\textsuperscript{100} Adding hydrocortisone to dexamethasone can reduce neuropsychological adverse effects, possibly by reducing the cortisol depletion in the cerebral mineralocorticoid receptors.\textsuperscript{101}

Vincristine does not typically cause significant myelosuppression and is given weekly during induction therapy and as monthly or tri-monthly pulses with glucocorticoids during continuation at doses of 1.5-2.0 mg/m\textsuperscript{2}. However, its adverse effects include peripheral sensory and motor neuropathy, and the dose is typically capped at 2.0 mg. A GWAS in children with ALL revealed that a polymorphism within the promoter region of \textit{CEP72} was associated with increased incidence and severity of vincristine-related peripheral neuropathy.\textsuperscript{102}

In many countries, polyethylene glycol (PEG)-\textit{Escherichia coli} L-asparaginase (pegaspargase) has replaced native \textit{E. coli} L-asparaginase, compared with which pegaspargase has a longer half-life and a lower incidence of hypersensitivity. Compared with intramuscular native \textit{E. coli} L-asparaginase, intravenous pegaspargase was similar-

---

### Table 3. Risk factors in pediatric acute lymphoblastic leukemia

| Factor                      | Better                                                                 | Worse                                                                 |
|-----------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Patient and clinical characteristics | Age at diagnosis: 1 to <10 years                                       | <1 year or ≥10 years                                                  |
|                             | Sex: Female                                                           | Male                                                                 |
|                             | Race: Caucasian, Asian                                                | African American, Hispanic                                           |
|                             | WBC counts at diagnosis: <50 × 10\textsuperscript{9}/L               | ≥50 × 10\textsuperscript{9}/L                                                        |
|                             | CNS involvement at diagnosis: CNS 1                                   | CNS 2 and CNS 3, traumatic tap with blasts                           |
|                             | Testicular involvement: No                                           | Yes                                                                   |
|                             | Immunophenotype: B-ALL                                                | T-ALL                                                                 |
| Cytogenetic and genetics    | High hyperdiploidy (51-65 chromosomes)                                | Hypodiploidy (<44 chromosomes)                                       |
|                             | \textit{ETV6-RUNX1}: t(12;21)(p13.2;q22.1)                            | \textit{KMT2A} rearrangement: t(v;11q23.3)                            |
|                             | \textit{NUMT1} rearrangement                                         | \textit{BCR-ABL1}: t(9;22)(q34.1;q11.2) (Ph+)                        |
|                             | \textit{BCR-ABL1-like} (Ph-like)                                      | \textit{TCF3-HLF}: t(17;19)(q22p13)                                  |
|                             | \textit{MEF2D} rearrangement                                          | \textit{Intrachromosomal amplification of chromosome 21 (iAMP21)}|
|                             | \textit{BCL2} or \textit{MYC} rearrangements                         | \textit{BCL2} or \textit{MYC} rearrangements                       |
| Minimal residual disease    | Negative                                                               | Positive                                                              |
|                             | Continuous decreasing and becoming negative                          | Increasing and/or persistently positive while monitored              |

WBC: white blood cell; CNS: central nervous system; ALL: acute lymphoblastic leukemia; Ph: Philadelphia chromosome.
ly efficacious, no more toxic, and associated with decreased patient anxiety at administration (Table 1).6 Although pegaspargase is typically used at 1000 IU/m² to 2500 IU/m², a therapeutic drug monitoring study showed trough levels of asparaginase activity of >100 IU/L even with administration at 450 IU/m² every two weeks.108 Interestingly, the incidence of asparaginase-related toxicities (e.g., pancreatitis, central neurotoxicity, and thrombosis) was not associated with asparaginase activity levels except in the case of liver toxicities. In a randomized study to assign non-high-risk patients to either ten continuous doses (2-week intervals) or three intermittent doses (6-week intervals) of intramuscular pegaspargase (1000 IU/m²), after receiving five doses every two weeks, asparaginase-related toxicities (hypersensitivity, osteonecrosis, pancreatitis, and thromboembolism) were significantly reduced in the latter group without compromising disease-free survival (DFS), suggesting that prolonged continuous administration of pegaspargase might not be necessary in the context of multiagent chemotherapy.109 Most allergic reactions to pegaspargase occur after two or three doses, and are mediated by the PEG moiety and not by the L-asparaginase, possibly because of the patients’ exposure to other PEG-containing products, such as laxatives and tablet coatings, before the diagnosis of ALL.110 Although adding rituximab to ALL therapy decreased the allergic reaction to native E. coli L-asparaginase and improved the outcome in adults with CD20-positive Ph-negative ALL,110 the efficacy of rituximab on PEG-related allergy is unknown. Discontinuation of planned asparaginase doses is associated with worse prognosis in high-risk patients.117 In cases of allergy to pegaspargase or native E. coli asparaginase, Erwinia asparaginase (Erwinase) is considered an acceptable alternative. However, Erwinia is more expensive, is intermittently unavailable, and requires frequent administration because of its short half-life.118 Universal premedication with diphenhydramine and an H2-blocker can decrease the incidence of allergic reactions,119 and drug desensitization in patients with previous and persistent anti-PEG antibodies is feasible.120

**Consolidation (intensification) therapy**

Induction with the 3- or 4-drug regimen (the IA phase) is followed by consolidation (the IB phase) with cyclophosphamide, cytarabine, and mercaptopurine. In patients with B-ALL, 5-year EFS was 92.5% for those with negative MRD at the end of both the IA phase (day 33) and the IB phase (day 78), which was better than the 5-year EFS for those with positive MRD at one or both time points but at a level of <10⁻³ on day 78 (77.6%) and for those with positive MRD at a level of ≥10⁻³ on day 78 (50.1%).111 Interestingly, the MRD level on day 33 in patients with T-ALL was not relevant if MRD was negative on day 78, suggesting the importance of the IB phase in T-ALL.122 Similarly, in ETP ALL, which is often associated with poor early response to 4-drug induction, IB-phase consolidation is effective at reducing MRD,113 and outcomes were comparable among patients with ETP, near-ETP, and non-ETP ALL in the Children’s Oncology Group AALL0434 study.114

Methotrexate is crucial for controlling systemic leukemia and also CNS and testicular disease. Methotrexate is administered as a high dose (2-5 g/m²) plus leucovorin rescue, together with 6-mercaptopurine, or as escalating intermediate doses of methotrexate (100-300 mg/m²) without leucovorin rescue followed by asparaginase (the Capizzi regimen). In randomized studies, high-dose methotrexate was superior to the Capizzi methotrexate regimen in patients with high-risk B-ALL (Table 1).1 Interestingly, in patients with T-ALL, Capizzi methotrexate was associated with better outcomes than high-dose methotrexate (Table 1). However, approximately 90% of the patients received cranial irradiation, and those in the high-dose methotrexate arm underwent irradiation five months later than those in the Capizzi regimen arm. As cranial irradiation can control both CNS and systemic relapses, this difference in timing of irradiation might have contributed to the different outcomes.

In a randomized trial of nelarabine in patients with intermediate- or high-risk T-ALL, the 5-year DFS and CNS relapse (isolated and combined) rates were significantly better in patients who received nelarabine than in those who did not (88.2% vs. 82.1% and 1.3% vs. 6.9%, respectively).110 Consolidation therapy is followed by reinduction (delayed intensification) therapy, which consists of medication similar to that used during the IA and IB phases and is a critical component of ALL therapy in both standard-risk and high-risk patients. Reducing the duration and chemotherapy doses of delayed intensification led to an increased incidence of relapse in standard-risk patients, especially those who did not have ETV6- RUNX1-positive ALL or were aged ≥7 years at diagnosis.115

**Maintenance therapy**

Maintenance therapy typically lasts ≥1 year and consists of daily mercaptopurine and weekly methotrexate with or without vincristine and steroid pulses. One study found that completing maintenance therapy at one year after diagnosis resulted in a high relapse rate (38.8±2.8% at 12 years after diagnosis), although this approach cured more than half of the children with ALL, and some genetic subgroups, such as TCF3-PBX1 and ETV6-RUNX1, were associated with excellent DFS.116 There is interpatient variability in mercaptopurine tolerance. Inherited heterozygous or homozygous deficiency of thiopurine methyltransferase (TPMT) leads to higher levels of active thiopurine metabolites and excess hematologic toxicities, which are more common in patients of European descent.6 For patients with East Asian or Native American ancestry, germline variants of NUDT15, which encodes a nucleoside diphosphatase, reduce degradation of active thiopurine nucleotide metabolites and were strongly associated with mercaptopurine intolerance.6 Therefore, thiopurine dosing adjustments based on TPMT and NUDT15 genotypes are recommended.118 Adherence of <95% to planned daily mercaptopurine doses is associated with a 2.7-fold increase in incidence of relapse compared with that seen when adherence is ≥95%.119 Confirming adherence by directly asking patients or by measuring their erythrocyte thioguanine nucleotide levels is important, especially for patients with persistently high WBC counts or absolute neutrophil counts, although self-reporting can overestimate the true intake in non-compliant patients. Patients were previously instructed to take mercaptopurine in the evening and without food/dairy products, but these restrictions did not affect outcomes or erythrocyte thioguanine
nucleotide levels as long as daily doses were administered at the same time of day.\textsuperscript{120}

**Central nervous system-directed therapy**

Because of the high risk of late neurocognitive sequelae, endocrinopathy, and secondary cancers, cranial irradiation has been largely replaced by intrathecal chemotherapy, in addition to systemic chemotherapy that has CNS effects (e.g., dexamethasone, high-dose methotrexate, and asparaginase). In an international meta-analysis, cranial irradiation decreased the incidence of isolated CNS relapse in patients with overt CNS involvement at diagnosis (CNS 3) but the cumulative incidences of any event and the OS were similar to those in patients who did not receive cranial irradiation.\textsuperscript{121}

The St. Jude Total XVI study used intensified intrathecal therapy during induction therapy and obtained a remarkable reduction in 5-year cumulative isolated and combined CNS relapses to 1.3% and 1.5%, respectively, without cranial irradiation (Table 1).\textsuperscript{9} In addition to CNS 3 at diagnosis, CNS 2 status (≤5 WBC/μL and blasts) at diagnosis is associated with worse outcomes and greater risk of CNS relapse, and augmented intrathecal chemotherapy is required.\textsuperscript{122} Traumatic lumbar puncture at diagnosis can introduce circulating ALL blasts into the cerebrospinal fluid (CSF) and is also associated with worse outcomes. Delaying the first intrathecal therapy until circulating blasts had disappeared improved the control of CNS disease.\textsuperscript{123}

Acute lymphoblastic leukemia blasts are typically detected in CSF by morphologic evaluation of cytospin samples. Flow cytometric analysis of CSF improved ALL blast detection, and positive results were associated with a higher incidence of any relapse,\textsuperscript{124} although another study failed to show such an association.\textsuperscript{125}

**Molecularly targeted agents**

With the increased understanding of genetic alterations in ALL, approaches targeting the driving genetic mutation and/or the associated signaling pathway are emerging (Table 2).\textsuperscript{126} Such an approach is attractive as it can augment or replace conventional chemotherapy with fewer off-target effects. In pediatric Ph-positive ALL, adding an ABL1 tyrosine kinase inhibitor, imatinib mesylate (540 mg/m\textsuperscript{2}/day), to intensive post-induction chemotherapy resulted in outcomes similar to those in patients who received HCT.\textsuperscript{127} Newer generations of tyrosine kinase inhibitors are available, and a randomized study showed that pediatric patients who received chemotherapy with 80 mg/m\textsuperscript{2}/day of dasatinib, a dual ABL/SRC inhibitor with more potent activity against BCR-ABL1 and better CNS penetration than imatinib, had better EFS, OS, and CNS disease control when compared to patients who received imatinib (300 mg/m\textsuperscript{2}/day).\textsuperscript{128} Ponatinib has potent activity in both wild-type and mutant BCR-ABL\textsubscript{1} ALL, including cells harboring the gatekeeper ABL1 T315I mutation. Combination chemotherapy with ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) alternating with high-dose methotrexate and cytarabine resulted in excellent 2-year EFS in adults with newly diagnosed Ph-positive ALL.\textsuperscript{129} Because of the potential adverse effects, such as thrombosis and pancreatitis, the safety of ponatinib in combination with pediatric regimens should be evaluated.

For patients with Ph-like ALL and ABL-class gene fusions (ABL\textsubscript{1}, ABL2, CSF1R, LYN, PDGFR\textalpha, or PDGFR\textbeta), ABL1 inhibitors can be combined with chemotherapy.\textsuperscript{129,130} For those patients with alterations that activate the JAK-STAT signaling pathway, such as rearrangements or a mutation of CRLF2 (IGH-CRLF2, P2RY8-CRLF2, or CRLF2 F232C), rearrangements of JAK2, EPOR, or TYK2, or mutations/deletions of IL7R, SH2B3, JAK1, JAK3, TYK2, or IL2RB, clinical trials of a JAK inhibitor, ruxolitinib, are ongoing.

Venetoclax inhibits the anti-apoptotic regulator BCL-2. Deregulated cell death pathways contribute to treatment failure in ALL.\textsuperscript{131} Preclinical studies have identified activities of venetoclax against high-risk leukemias such as ETP ALL, KMT2A-rearranged ALL, TCF3-HLF-positive ALL, and hypodiploid ALL (Table 2).\textsuperscript{132,133} Proteasome and mTOR inhibitors have shown efficacy in relapsed ALL.\textsuperscript{134,135} DOT1L, bromodomain, menin, and histone deacetylase inhibitors have shown promise in preclinical studies as therapies targeting unique molecular characteristics of KMT2A-rearranged ALL.\textsuperscript{136}

**Immunotherapy**

Immunotherapy can be given as antibody-based therapy (e.g., blinatumomab or inotuzumab ozogamicin) or T-cell-based therapy (chimeric antigen receptor T [CAR T] cells, e.g., tisagenlecleucel), which have improved the response rate and outcomes in patients with relapsed/refractory B-ALL (Figure 4).\textsuperscript{137} Antibodies (e.g., daratumumab directed against CD38) and CAR T cells (e.g., targeting CD1a, CD5, and CD7) against T-ALL are also under investigation.

Blinatumomab has two different single-chain Fv fragments: one binds the CD3 antigen and activates T-cell cytotoxicity, and the other binds the B-cell antigen CD19, which is expressed on most B-ALL cells.\textsuperscript{138-140} In a randomized study of adults with refractory/refractory B-ALL, patients who received blinatumomab had a better complete remission rate and survival than those who received the standard-of-care chemotherapy,\textsuperscript{141} and blinatumomab was effective in eradicating MRD.\textsuperscript{142} Patients aged 1-30 years with intermediate- or high-risk relapsed B-ALL were randomized to receive either two blocks of intensive chemotherapy or two 4-week blocks of blinatumomab after receiving re-induction chemotherapy.\textsuperscript{143} The blinatumomab arm had better 2-year DFS, OS, and MRD clearance and lower incidences of febrile neutropenia, infection, and sepsis when compared with the chemotherapy arm. Cytokine release syndrome and neurotoxicity are adverse effects of blinatumomab, and their incidence and severity can be reduced by decreasing the disease burden before treatment.

Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody conjugated to calicheamicin.\textsuperscript{144-146} A randomized study in adults with refractory/refractory B-ALL showed that patients who received inotuzumab had a better remission rate and survival than did patients who received standard chemotherapy.\textsuperscript{147} In a pediatric inotuzumab compassionate-use program, complete remission was seen in 67% of 51 children with relapsed/refractory ALL.\textsuperscript{148} Inotuzumab is associated with sinusoidal obstruction syndrome, especially after HCT.\textsuperscript{149,150} Fractionated use of low-dose inotuzumab and a longer interval between inotuzumab treatment and HCT can reduce the incidence of this syndrome.

Chimeric antigen receptor T cells express a synthetic
receptor consisting of a single-chain variant fragment (scFv) domain directed against a B-lineage–associated antigen (e.g., CD19 and CD22) and intracellular signaling domains such as 4-1BB or CD28 with CD3ζ.144 A study of CD19 CAR T cells in children and young adults with relapsed/refractory B-ALL showed a complete remission rate of 81% with 12-month EFS and OS of 50% and 76%, respectively.144 CAR T cells can migrate to extramedullary sites such as the CNS and testes; therefore, they can be considered not only for patients with isolated bone marrow relapses but also for those with isolated or combined extramedullary relapses.145 The persistence of CAR T cells and B-cell aplasia are important factors in long-term remission unless there is loss of the target antigen.145,146 Therefore, CAR T cells have been developed that can target other antigens (e.g., CD22 or the thymic stromal lymphopoietin receptor) or simultaneously target dual antigens (e.g., CD19/CD22).146 As with blinatumomab, cytokine release syndrome and neurotoxicity are major adverse effects. Tocilizumab (an anti-IL-6 receptor antibody) and/or steroid have been used to ameliorate these effects, and early intervention in patients who are developing signs of cytokine release syndrome is effective without compromising the anti-leukemia potency of CAR T cells.147 Although CAR T cells can be curative by themselves, some consider them as a bridging therapy to subsequent HCT.148

To monitor MRD and antigen escape, the leukemia population should be characterized by multiparametric flow cytometry without using the targeted antigen prior to immunotherapy.146 Alternately, PCR or next-generation sequencing methods can be used.

**Future perspectives**

Comprehensive sequencing and integrative genome-wide analyses have profoundly refined the taxonomy of ALL, resulting in the identification of new entities with prognostic and therapeutic significance. There are distinct gene expression patterns in ALL caused by a wide range of genetic alterations that converge on specific pathways. Identifying these pathways is crucial for therapeutic targeting and demands the incorporation of gene expression approaches into the clinical diagnostic work-up of ALL. Mutation-agnostic approaches, such as drug sensitivity testing of panels of chemotherapeutic agents ex vivo and functional genomic screens, also offer the promise of identifying new therapeutic vulnerabilities and efficacious combinations.149 Such intervention would lead to new therapeutic strategies incorporating individualized mutation-directed targeted therapy, immunotherapy, and reduced-intensity conventional chemotherapy or a chemotherapy-free regimen, which would ultimately improve patient survival and reduce adverse effects.

**Acknowledgments**
The authors thank colleagues at St. Jude Children’s Research Hospital, the Children’s Oncology Group, and multiple centers...
References

1. Moricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone versus prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101-2112.
2. Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukaemia: a report from Children’s Oncology Group Study AALL0322. J Clin Oncol. 2016;34(23):2360-2368.
3. Maloney KW, Devidas M, Wang C, et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukaemia: results of Children’s Oncology Group Trial AALL0531. J Clin Oncol. 2020;38(9):602-612.
4. Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0484 Methotrexate Randomization. J Clin Oncol. 2018;36(14):1355-1363.
5. Place AE, Stevenson KE, Vrooman LM, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukaemia, and minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2291-2297.
6. Pieters R, de Groot-Kruisman H, Van der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukaemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2291-2297.
7. Vora A, Gouwen N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL) 2008: a randomised controlled trial. Lancet. 2015;15(10):509-518.
8. Toft N, Birgens H, Abrahamsson J, et al. Improved outcome in children with standard-risk B-lineage acute lymphoblastic leukemia: results of Children’s Oncology Group Study AALL0531. J Clin Oncol. 2020;38(9):602-612.
9. Jeha S, Pei D, Choi J, et al. Improved CNS prophylaxis in acute lymphoblastic leukemia. Nat Genet. 2013;45(10):1226-1231.
10. Noetzel L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETFV are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47(5):555-558.
11. Mullighan CG, Gooistra S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.
12. Gu Z, Churchman ML, Roberts KG, et al. PAXS-drug resistant B-precursor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296-307.
13. Churchman ML, Qian M, Te Kronnie G, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018;33(5):957-968.
14. Kuehn HS, Boisson B, Cunningham-Rundles C, et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043.
15. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 in B-lineage acute lymphoblastic leukaemia is characterised by the deletion of Ikaros. Nature. 2008;453(719):110-114.
16. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia. N Engl J Med. 2009;360(5):470-480.
17. Zhang J, McCastlain K, Yoshihara H, et al. Deregression of DUX4 and EGR2 in acute lymphoblastic leukaemia. Nat Genet. 2016;48(12):1481-1489.
18. Brown AL, Arts P, Carmichael CL, et al. RUNX1-mutated mice show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020;4(6):1131-1144.
19. Feurstein S, Godley LA. Germline ETV6 filip unique to germline predisposed AML. Blood Adv. 2020;4(4):672-675.
20. Greaves M. Pre-natal origins of childhood leukaemia. Rev Clin Exp Hematol. 2003;7(3):235-245.
21. Greaves M, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2005;107(2):2531-2533.
22. Feurstein S, Godley LA. Germline ETV6 mutations in myelodysplasia: a somatic driver revealed by whole-genome sequencing of twins with acute myelodysplastic syndrome. Genes Chromosomes Cancer. 2019;58(10):723-730.
23. Poulout GP, Deger J, Hinze L, et al. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukaemia. FlOx One. 2019;14(11):e0221288.
24. Winer F, Muskins IS, Walsh KM, et al. Germline variants in patients with Down syndrome and acute lymphoblastic leukemia. Blood Adv. 2020;4(4):672-675.
25. Trevino LR, Yang W, French D, et al. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukaemia in children. Genes Chromosomes Cancer. 2017;56(12):1500-1505.
26. de Smuk AJ, Lavoie G, Walsh KM, et al. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukaemia in children. J Nat Cancer Inst. 2019;111(12):1550-1557.
27. de Smuk AJ, Lavoie G, Walsh KM, et al. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukaemia in children. Genes Chromosomes Cancer. 2019;58(10):723-730.
Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2506-2514.

43. Lilleheijmo H, Henningsson R, Hyrenius-Wittsten A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.

44. Zaliova M, Kotrova M, Bresolin S, et al. Intragenic amplification of PAX5: a novel translocation resulting in MEF2D-BCL9 fusion gene is associated with acute lymphoblastic leukemia. Cancer Cell. 2019;26(1):1473-1477.

45. Li JF, Dai YT, Lilljebjorn H, et al. Activating mutations of NOTCH1 in human early immature human T cell leukemias. J Exp Med. 2011;210(13):2571-2579.

46. Della Gatta G, Falpofaro AA, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemia. J Exp Med. 2011;210(13):2571-2579.

47. Zhang J, Ding L, Holmfeldt L, et al. Small genomic insertion forms enhancers that misregulate oncogenes. Nat Commun. 2017;8:14385.

48. Van Vlierberghe P, Ambesi-Impiombato A, van der Logt R, et al. Small genomic insertions form enhancers in primary lymphoid leukemias. Cancer Disc. 2020;10(4):568-587.

49. Chatzimavroudi A, Nusbaum H, Kassiotis G, et al. The genetics and mechanisms of T-cell acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2020 Mar 2.[Epub ahead of print].

50. Liu Y, Easton J, Shao Y, et al. The genomic landscape of intratumorally arising adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49(9):1211-1218.

51. Janssen P, Boissel N, Sigaux F, et al. The clinical and molecular characteristics of MEF2D fusions in acute lymphoblastic leukemia. Leukemia. 2019;33(11):1235-1242.

52. Guerin F, Belver L, Fernando A. The genetics and mechanism of T-cell acute lymphoblastic leukemia. Leukemia. 2015;29(12):2301-2314.

53. Weng AP, Ferrando AA, Lee W, et al. Relapse-specific mutations in NOTCH1 in human acute lymphoblastic leukemia. Leukemia. 2014;28(7):1280-1289.

54. Mullighan CG, Zhang J, Rasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471(7343):255-259.

55. Palomero T, Lim WK, Odom DT, et al. The genetic basis and cell of origin of mixed phenotype acute leukemia. Nature. 2016;52(7727):373-379.

56. Li JF, Dai YT, Lilljebjorn H, et al. Activating enhancer-promotor T cell development, activates a feed-forward-loop transcriptional network identifies RUNX1 like T-cell acute lymphoblastic leukemia. Cancer Cell. 2017;31(6):1325-1332.

57. Gianni F, Belver L, Ferrando A. The genetics and mechanisms of T-cell acute lymphoblastic leukemia. Leukemia. 2015;29(12):2301-2314.

58. Alley LB, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(18):41-55.

59. Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(18):41-55.

60. Mullighan CG, Zhang J, Rasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471(7343):255-259.

61. Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(18):41-55.

62. Palomero T, Lim WK, Odom DT, et al. The genetic basis and cell of origin of mixed phenotype acute leukemia. Nature. 2016;52(7727):373-379.

63. Li JF, Dai YT, Lilljebjorn H, et al. Activating enhancer-promotor T cell development, activates a feed-forward-loop transcriptional network identifies RUNX1 like T-cell acute lymphoblastic leukemia. Cancer Cell. 2017;31(6):1325-1332.

64. Palomero T, Lim WK, Odom DT, et al. The genetic basis and cell of origin of mixed phenotype acute leukemia. Nature. 2016;52(7727):373-379.
lineage leukemia. Blood. 2018;132(3):264-276.

92. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation partners and therapeutic opportunities. Nat Genet. 2015;47(9):1020-1029.

93. Pui CH, Fei D, Raimondi SC, et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia. 2017;31(2):383-390.

94. Conner D, Eshbaei A, Bartrum J, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2016;36(1):54-63.

95. Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2016;131(12):1589-1599.

96. Mulrooney DA, Hyun G, Ness KK, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019;6(6):e306-e316.

97. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukemia. N Engl J Med. 2013;368(3):276-287.

98. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukemia. J Clin Oncol. 2017;35(23):2051-2061.

99. Alexander S, Fisher BT, Gaur AH, et al. Genotyping predicts pegaspargase allergic reactions and failure of relapse. J Clin Oncol. 2019;37(23):2051-2061.

100. Liu Y, Smith CA, Panetta JC, et al. Association of asparaginase pegaspargase allergic reaction to initial CSF findings on outcome. J Clin Oncol. 2016;34(19):2051-2061.

101. Gupta S, Wang C, Raette EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2015;33(19):2051-2061.

102. Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2015;125(4):507-514.

103. Cooper SL, Young DJ, Arwood NM, Poggi SG, Brown PA. Universal pre-medication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(6):e27797.

104. Swanson HD, Panetta JC, Barker PJ, et al. Predicting success of desensitization after pegaspargase allergy. Blood. 2020;155(1):71-75.

105. Conter V, Bartrum CR, Valacchi MG, et al. Molecular response to treatment redlines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 5184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.

106. Schrappe M, Valacchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukemia in children treated in AIEOP centres with AIEOP-BFM-protocols: a retrospective analysis. Lancet Haematol. 2016;3(2):e80-e88.

107. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2016;30(6):775-788.

108. Dunsmore KR, Winter SS, Devidas M, et al. Children’s Oncology Group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38(8):580-584.

109. Schrappe M, Beckmann K, Zimmermann M, et al. Reduced-intensity delayed intensified standard-risk pediatric acute lymphoblastic leukemia: results of an international randomized trial (AIEOP-BFM-ALL 2000). J Clin Oncol. 2018;36(5):244-253.

110. Kato M, Ishimaru S, Seki M, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL03S1. Leukemia. 2014;28(7):1467-1471.

111. Shen S, Chen X, Cai J, et al. Effect of dasatinib versus imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):407-414.

112. Jabbour E, Kantarjian H, Ravanji F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547-1555.

113. Robert KS, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. Cell Death Dis. 2019;10(8):571.

114. Tanasi I, Ba I, Sirvent N, et al. Efficacy of ciscloxad in standard-risk pediatric acute lymphoblastic leukemia. JAMA. 2013;310(15):1580-1588.

115. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicity: a NOPHO ALL2006 randomized study. J Clin Oncol. 2019;37(19):1638-1646.

116. Liu Y, Smith CA, Panetta JC, et al. Association of asparaginase pegaspargase allergic reaction and failure of relapse. J Clin Oncol. 2019;37(23):2051-2061.

117. Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044-1053.

118. Gupta S, Wang C, Raette EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2015;33(19):2051-2061.

119. Conter V, Bartrum CR, Valacchi MG, et al. Molecular response to treatment redlines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 5184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.

120. Schrappe M, Valacchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukemia in children treated in AIEOP centres with AIEOP-BFM-protocols: a retrospective analysis. Lancet Haematol. 2016;3(2):e80-e88.

121. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2016;30(6):775-788.

122. Dunsmore KR, Winter SS, Devidas M, et al. Children’s Oncology Group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38(8):580-584.

123. Kato M, Ishimaru S, Seki M, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL03S1. Leukemia. 2014;28(7):1467-1471.

124. Shen S, Chen X, Cai J, et al. Effect of dasatinib versus imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):407-414.

125. Seyfried F, Demir S, Horl RL, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signal-regulating kinase 1 (ASK1) and AKT activity. Blood. 2016;128(21):2582-2590.

126. Diaz-Flores E, Comeaux EQ, Kim KL, et al. Bin-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 2019;79(9):2339-2351.

127. Messinger YH, Gately PS, Sporzo R, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128(10):1582-1595.

128. Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128(10):1582-1595.

129. Patel A, Reardon DA, Koehl S, et al. Efficacy of lenalidomide in relapsed Philadelphia positive acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019;134(16):1551-1555.

130. Tanasi I, Ba I, Sirvent N, et al. Efficacy of ciscloxad in standard-risk pediatric acute lymphoblastic leukemia. JAMA. 2013;310(15):1580-1588.

131. Bhatia S, Landier W, Hagerman L, et al. Systemic exposure to thalidomide and risk of relapse in children with acute lymphoblastic leukemia: a Children’s Oncology Group Study. JAMA Oncol. 2015;1(3):287-295.

132. Landier W, Hagerman L, Chen Y, et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group Study AALL03S1. J Clin Oncol. 2017;35(15):1730-1736.
136 Brown P, Pieters R, Biondi A. How I treat infant leukemia. Blood. 2019;133(3):205-214.

137 Inaba H, Pui CH. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev. 2019;38(4):595-610.

138 Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.

139 Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.

140 Brown PA, Ji L, Xu X, et al. A randomized phase 3 trial of blinatumomab versus chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children’s Oncology Group Study AALL1331. Blood. 2019;134(Suppl 2):LBA-1.

141 Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.

142 Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884-892.

143 Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230-234.

144 Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.

145 Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.

146 Shah NN, Fry T. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-385.

147 Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149-2158.

148 Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325-2338.

149 Frismantas V, Dobay MP, Rinaldi A, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129(11):e26-e37.